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We treated 14 patients with GATA2 deﬁciency using a nonmyeloablative allogeneic hematopoietic stem cell
transplantation regimen. Four patients received peripheral blood stem cells from matched related donors
(MRD), 4 patients received peripheral blood stem cells from matched unrelated donors (URD), 4 patients
received hematopoietic stem cells from umbilical cord blood donors (UCB), and 2 patients received bone
marrow cells from haploidentical related donors. MRD and URD recipients received conditioning with 3 days
of ﬂudarabine and 200 cGy total body irradiation (TBI). Haploidentical related donor recipients and UCB
recipients received cyclophosphamide and 2 additional days of ﬂudarabine along with 200 cGY TBI. MRD,
URD, and UCB recipients received tacrolimus and sirolimus for post-transplantation immunosuppression,
whereas haploidentical recipients received high-dose cyclophosphamide followed by tacrolimus and myco-
phenolate mofetil. Eight patients are alive with reconstitution of the severely deﬁcient monocyte, B cell, and
natural killer cell populations and reversal of the clinical phenotype at a median follow-up of 3.5 years. Two
patients (1 URD recipient and 1 UCB recipient) rejected the donor graft and 1 MRD recipient relapsed with
myelodysplastic syndrome after transplantation. We are currently using a high-dose conditioning regimen
with busulfan and ﬂudarabine in patients with GATA2 deﬁciency to achieve more consistent engraftment and
eradication of the malignant myeloid clones.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Expression of the GATA2 transcription factor is tightly
regulated during hematopoiesis, and both over- and under-
expression of GATA2 have been associated with myelodys-
plastic syndrome (MDS) and acute myelogenous leukemia
(AML) [1,2]. Recently, heterozygous sporadic or inherited
mutations on 1 allele of the GATA2 gene have been shown to
be responsible for a syndrome known variably as MonoMAC
(monocytopenia with nontuberculous mycobacterial in-
fections (NTM)) [3]; dendritic, monocytes, and lymphoid
cell deﬁciency [4]; Emberger’s syndrome (congenitaledgments on page 1948.
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c. on behalf of American Society for Blood andlymphedema with MDS and monosomy 7) [5]; and familial
MDS/AML [2].
Allogeneic hematopoietic stem cell transplantation
(HSCT) represents a potentially curative therapy for patients
with GATA2 deﬁciency; however, these patients pose a
particular therapeutic challenge because of the frequent
comorbidities associated with this disease. These comor-
bidities include life-threatening infections secondary to
deﬁciency of monocytes, natural killer (NK) cells, and B cells,
as well as pulmonary alveolar proteinosis (PAP) resulting
from defective alveolar macrophages [6,7]. In addition, the
MDS in patients with GATA2 deﬁciency has the propensity to
transform into AML or proliferative chronic myelomonocytic
leukemia (CMML) [8].
We used a nonmyeloablative transplantation regimen to
treat patients with GATA2 deﬁciency because the majority ofMarrow Transplantation.
J. Grossman et al. / Biol Blood Marrow Transplant 20 (2014) 1940e1948 1941patients in our initial cohort had severe underlying organ
dysfunction and active infections at the time of trans-
plantation. In 2011, we published a pilot study describing
encouraging results using a nonmyeloablative regimen in 6
patients with GATA2 deﬁciency [9]. Here, we describe the
outcomes of the ﬁrst 14 patients who received non-
myeloablative allogeneic HSCT for this newly described ge-
netic syndrome, including the ﬁrst 2 patients to receive a
haploidentical transplant.
PATIENTS AND METHODS
Patients
This study was designed to determine the efﬁcacy and safety of non-
myeloablative allogeneic HSCT for patients with GATA2 deﬁciency, or
MonoMAC syndrome, andwas approved by the institutional review board of
the National Cancer Institute. This study was independently monitored for
safety and data accuracy (ClinicalTrials.gov number, NCT00923364). Patients
between 12 to 60 years of agewere eligible if theymet the following criteria:
(1) at least 2 episodes of life-threatening opportunistic infections; (2) mu-
tation in the GATA2 gene, or a ﬂow cytometry proﬁle on peripheral blood
demonstrating severe monocytopenia and CD19þ B cell and CD3CD56þ NK
cell lymphopenia, consistent with the MonoMAC phenotype [10]; and (3) a
10/10 or 9/10 matched related donor (MRD) or matched unrelated donor
(URD), a 4/6 or greater matched umbilical cord blood donor (UCB), or a
haploidentical related donor.
Patients were allowed to have MDS with 1 or more peripheral blood
cytopenias and less than 5% blasts in the bone marrow in the absence of
granulocyte colonyestimulating factor.
Characteristics of Allogeneic HSCT
MRD and URD were required to be 18 years of age or older and matched
at 10/10 or 9/10 HLA-A, -B, -C, -DRB1, and -DQB1 loci by high-resolution
typing [11]. In addition, MRD and haploidentical related donors were
required to have either a normal GATA2 gene on DNA sequencing or normal
blood monocyte, NK cell, and B cell counts, and no history of mycobacterial
or any other opportunistic infections.
Haploidentical related donors were required to share 1 haplotype in
common with the recipient, such that HLA compatibility represented a
minimum match of 5 out of 10 HLA loci. As with MRDs, exclusion criteria
included mutation in GATA2, history of mycobacterial or other opportunistic
infections, or abnormal monocyte, NK, or B cell counts. If more than 1
haploidentical donor were available, each donor was evaluated individually
in terms of overall health, ABOmatching, and cytomegalovirus (CMV) status,
etc. to select the best donor.
The conditioning regimen depended upon the type of donor graft. MRD
or URD recipients received ﬂudarabine 30 mg/m2/day on days 4, 3,
and 2, and 200 cGy total body irradiation (TBI) on day 1. UCB recipients
received cyclophosphamide 50 mg/kg i.v. on day6, ﬂudarabine 30 mg/m2/
day i.v. for 5 days (days6 to2), and 200 cGy TBI on day -1. Haploidentical
related donor recipients received ﬂudarabine 30 mg/m2/day i.v. for 5 days
(days 6 to 2), cyclophosphamide 14.5 mg/kg i.v. for 2 days (days 6
and 5), and 200 cGy TBI on day 1 [12].
The cell product also depended upon the type of transplant. MRD and
URD received peripheral blood stem cells from their donors obtained using
5 days of granulocyte colonyestimulating factor (ﬁlgrastim) (10 mg/kg/day)
followed by apheresis with the goal of collecting at least 5106 CD34þ cells/
kg of the recipient’s body weight. MRD and URD peripheral blood stem cells
were infused fresh on day 0. Umbilical cord blood units were thawed and
infused on day 0. Haploidentical related donor recipients received fresh or
cryopreserved bonemarrow cells on day 0, with a target dose of 2108 total
nucleated cells per body weight of the recipient. Graft-versus-host-disease
(GVHD) prophylaxis was dependent upon the type of transplant. Tacroli-
mus and sirolimus were initiated on days 3 and 2, respectively, in MRD,
URD, and UCB recipients. The doses of both agents were titrated to achieve
serum levels between 5 and 10 ng/mL. Immunosuppression was tapered at
6 months after transplantation if there were no evidence of GVHD. Post-
transplantation immunosuppression for haploidentical recipients con-
sisted of cyclophosphamide 50 mg/kg/day i.v. for 2 days on days þ3 and þ4
followed by tacrolimus and mycophenolate mofetil starting on day þ5 [12].
Immunosuppression with mycophenolate was stopped at day þ30, and
immunosuppression with tacrolimus was tapered at 6 months after trans-
plantation if there were no evidence of GVHD.
Supportive Care
Standard guidelines for supportive care established at the National In-
stitutes of Health Clinical Center for patients undergoing allogeneic HSCTwere used. These guidelines are in agreement with the international
guidelines for preventing infectious complications among hematopoietic
cell transplantation recipients [13].
For NTM infections, infectious disease physicians with expertise in
therapy for NTM infection were involved in the care of these patients.
Treatment selection was based on the speciﬁc NTM species isolated [14].
When patients had their NTM infection fully treated before transplantation,
they were kept on prophylactic azithromycin until 1 year after trans-
plantation. In cases in which the NTM infection was recent, all efforts were
made to delay transplantation until the NTM infection was under control,
cultures became negative, and lesions were stable or regressing on imaging
studies. For patients whose infection episodes were recent or had bone
involvement andwere still on a rifamycin as part of their treatment, this was
changed to moxiﬂoxacin before the start of the conditioning regimen, to
avoid possible drug interactions. All patients had a macrolide as part of their
treatment regimen or secondary prophylaxis; in all cases, azithromycin was
selected over clarithromycin to avoid possible drug interactions. Most pa-
tients who were still being treated for active infection at the time of
transplantation (double or triple therapy) were kept on all the anti-
mycobacterial drugs at least 6 to 12 months after the transplantation. Sub-
sequently, these were discontinued, and the azithromycin was kept for at
least 6 more months.
Immune Reconstitution of T, B, and NK Cells and Monocytes
CD14þ monocytes, CD3/CD56þ NK cells, CD19þ B lymphocytes, and
CD3þ T lymphocytes were quantiﬁed by ﬂow cytometry using subset spe-
ciﬁc monoclonal antibodies before transplantation and at designated in-
tervals after transplantation.
Cytogenetics
Cytogenetic analysis was performed before transplantation and at
28 days and 12 months after transplantation. When cytogenetic abnor-
malities were present, ﬂuorescence in situ hybridization was used to iden-
tify the speciﬁc chromosomal abnormalities.
Analysis of Chimerism
Engraftment of donor cells was assessed using polymorphisms in re-
gions known to contain short tandem repeats. Peripheral blood CD14þ,
CD3/CD56þ, CD19þ, and CD3þ subsets were isolated by ﬂow cytometry at
designated time points, and chimerism was assessed. In addition, CD14þ/
CD15þ myeloid cells and CD3þ T lymphocytes were selected using immu-
nobeads and chimerism was assessed on the selected cells.
Statistical Analysis
Descriptive statistics were used for chimerism, monocyte, NK, and
lymphocyte counts.
RESULTS
Study Population
Baseline characteristics of the 14 patients with mutations
in GATA2, or MonoMAC syndrome, who received allogeneic
stem cell transplantation are shown in Table 1. The median
age at the time of transplantation was 33 years (range, 15 to
46 years). The majority of patients had suffered infections
since childhood. The median duration of illness before
transplantation was 7.5 years (range, 1 to 28 years). All pa-
tients had characteristic ﬂow cytometry ﬁndings in their
peripheral blood with severely reduced CD14þ monocytes,
CD19þ B lymphocytes, and CD3-/CD56þ NK cells, along with
normal to slightly reduced CD3þ T lymphocytes.
Susceptibility to opportunistic infections, especially with
NTM mycobacteria species, is a hallmark of MonoMAC syn-
drome, and all but 2 patients had a history of an NTM
infection (Table 1). Severe DNA viral infections, most
frequently human papillomavirus, were common, presum-
ably due to the lack of NK cells. One patient had a severe
refractory human herpes simplex virus infection. Over one
half of the patients in our cohort had serious fungal and/or
bacterial infections before transplantation.
Pulmonary diseasewas also common in this cohort with 5
patients having PAP (Table 1). Two patients were on sup-
plemental oxygen before transplantation because of this
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J. Grossman et al. / Biol Blood Marrow Transplant 20 (2014) 1940e1948 1943condition. The severity of the disease is evidenced by the fact
that 1 patient (patient 1) was considered to be a lung
transplantation candidate before HSCT and ultimately
received a double lung transplant 4 years after HSCT. In
addition, patient 2 underwent transplantation while
intubated after pretransplantation whole lung lavage for
severe PAP.
The patients in this study had a variety of mutations in
GATA2, the 2 most common being T354M and R398W
(Table 1). Patient 14 did not have an identiﬁable mutation in
an exon of GATA2 but expressed only the paternal allele of
GATA2 at the mRNA level. Five patients had a parent or sib-
ling with a GATA2mutation, and the remaining 9 patients did
not have a family history of the syndrome in a ﬁrst-degree
relative.
All patients had bone marrow involvement, with 12 pa-
tients (86%) meeting World Health Organization criteria for
MDS. Most patients had refractory cytopenia with multi-
lineage dysplasia at the time of diagnosis. Two patients had
progressed to refractory anemia with excess blasts before
transplantation (Table 2). In contrast to patients with typical
MDS, the majority of patients had bonemarrow biopsies that
were hypocellular with reticulin ﬁbrosis. On cytogenetic
analysis, 4 patients had monosomy 7, an abnormality known
to be associated with a poor prognosis in MDS and AML
(Table 2).
The typical progression of the bone marrow histology in
GATA2 deﬁciency is shown (patient 7) (Figure 1). Approxi-
mately 2 years before transplantation, her marrow was
hypocellular with reduced granulocyte precursors and
monocytes and normal cytogenetics (Figure 1A,B). Over a 2-
year period, her marrow became hypercellular with 5% to 7%
blasts, consistent with a diagnosis of refractory anemia with
excess blastse1, and cytogenetic analysis revealed a new
monosomy 7 (Figure 1C,D). Six months after inductionTable 2
Reversal of MDS and Cytogenetic Abnormalities after HSCT
Donor Patient Pretransplantation Bone Marrow Pretran
Treatm
Diagnosis Cytogenetics Cellularity*
MRD 1 RCMD Normal Hypocellular None
2 RCMD N/A Hypocellular None
3 RCMD Trisomy 1q Hypocellular
Gr 1-2 Fibrosis
None
4 RCMD Trisomy 8 Hypocellular
Gr 1-2 Fibrosis
None
URD 5 RCMD -Y Hypocellular
Gr 2 Fibrosis
None
6 RCMD Trisomy 8 Hypocellular
Gr 1-2 Fibrosis
None
7 RAEB1 Monosomy 7 Hypercellular 3 þ 7
RCMD Trisomy 8 Hypocellular None
UCB 9 RAEB2 Monosomy 6, þr Normocellular
Gr 3 Fibrosis
3 þ 7
10 RCMD Monosomy 7 Hypocellular None
11 RCMD Monosomy 7,
Trisomy 21
Hypocellular
Gr 2 Fibrosis
None
12 RCMD Monosomy 6 Hypocellular
Gr 2 Fibrosis
None
Haplo 13 CMML Monosomy -7q
Trisomy 8
Hypercellular
Gr 2 Fibrosis
HIDAC,
14 HLH, EBV (þ)
T cell LPD
Normal Hypocellular Alemtu
etoposi
RCMD indicates refractory cytopenia with multilineage dysplasia; ND, not done as
blasts; HIDAC, high-dose cytosine arabinoside; HLH, hemophagocytic lymphohisti
* Cellularity for age (100% - age  10%)
y Results of last available marrow. Patient 5 refused bone marrow biopsies
transplantation.chemotherapy and an unrelated donor transplantation, the
bone marrow histology and cytogenetic analysis were
normal (Figure 1E,F).
Pretransplantation chemotherapy was required in 3 pa-
tients. Two patients (patients 7 and 9) required 1 cycle of
chemotherapy with idarubicin and cytosine arabinoside
(7 þ 3) before transplantation because the bone marrow
blast count was greater than 5% (Table 2). One patient (pa-
tient 13) presented with an MDS/myeloproliferative syn-
drome (CMML) and received 3 cycles of chemotherapy (7þ 3,
then high-dose cytosine arabinoside and melphalan) before
transplantation. This patient had received chemotherapy for
AML 7 years earlier and had achieved a complete remission.
Transplantation Characteristics
This cohort of patients received a cross section of graft
sources with 4 MRD, 4 URD, 4 UCB, and 2 haploidentical
related donors. Peripheral blood stem cells were used in all
MRD and URD donors, and bone marrow was used for hap-
loidentical related donor recipients. Cell doses were com-
parable in the MRD, URD, and haploidentical related donor
groups (Table 3).
Reconstitution of Hematopoietic Compartments after
Transplantation
Reconstitution of the cellular compartments that were
severely deﬁcient before transplantation represented a pri-
mary objective of this study. The median time to neutrophil
engraftment (deﬁned as a neutrophil count of>.5109 cells/
L for 3 consecutive days) for recipients of MRD and URD was
12 days (range, 0 to 13 days). The 3 evaluable patients in the
UCB group engrafted neutrophils within a range from 16 to
80 days. Of the 2 haploidentical transplant recipients, the
ﬁrst patient died early after transplantation and the second
patient had neutrophil engraftment by day 19 aftersplantation
ent
Two-year Post-transplantation Bone Marrow
Diagnosis Cytogenetics Cellularity*
Trilineage hematopoiesis 46, XY Normocellular
ND ND ND
Trilineage hematopoiesis 46, XY Hypocellular
Gr 1 ﬁbrosis
Trilineage hematopoiesis 46, XX Hypocellular
Gr 1-2 ﬁbrosis
yTrilineage hematopoiesis 46, XX Normocellular
Gr 2 ﬁbrosis
Trilineage hematopoiesis 46, XX Hypocellular
Gr 1-2 ﬁbrosis
Trilineage hematopoiesis 46, XX Normocellular
Gr 1 ﬁbrosis
ND ND ND
Trilineage hematopoiesis 46, XY Hypocellular
Gr 3-4 ﬁbrosis
Trilineage hematopoiesis 46, XY Hypocellular
ND ND ND
ND ND ND
Melphalan ND ND ND
zumab,
de (HLH)
yTrilineage hematopoiesis,
no EBV detected
N/A Hypocellular
patient died before 2 years; Gr, grade; RAEB, refractory anemia with excess
ocytosis; LPD, lymphoproliferative disorder; N/A, not available.
as of 6 months after transplantation. Patient 9 is only 9 months after
Figure 1. Typical evolution of pathologic changes in the bone marrow in GATA2 deﬁciency. Bone marrow ﬁndings for patient 7. (A), (C), and (E) show bone marrow
biopsy results 2 years before transplantation, 2 months before transplantation, and 6 months after transplantation respectively. (B), (D), and (F) show bone marrow
aspirates from the same time points. This demonstrates the progression of the bone marrow from hypocellular to hypercellular and ﬁnally to normal trilineage
hematopoiesis.
J. Grossman et al. / Biol Blood Marrow Transplant 20 (2014) 1940e19481944transplantation. The pattern was similar for platelet
engraftment (deﬁned as a platelet count of >20  109 cells/L
for 7 consecutive days without requiring platelet trans-
fusion). MRD recipients engrafted at a median of 16 days
(range, 0 to 18 days), URD at 13 days (range, 0 to 18 days), the
2 evaluable UCB recipients engrafted at 32 and 302 days, and
the single, evaluable haploidentical related donor recipient
never had a platelet count below 20.Table 3
Characteristics of Hematopoietic Stem Cell Grafts and Outcome of HSCT
Donor Patient Cell
Source
HLA
Match
Composition of Donor Graft I
H
CD34þ  106/kg CD3þ  106/kg
MRD 1 PBSC 10/10 7.0 247 C
2 PBSC 10/10 4.1 380 I
v
3 PBSC 10/10 6.0 174 -
4 PBSC 10/10 6.4 330 -
URD 5 PBSC 10/10 6.87 354 -
6 PBSC 10/10 8.25 207 -
7 PBSC 9/10 7.25 447 -
8 PBSC 10/10 6.3 188 C
UCB 9 Single UC 4/6 .78 3.48 C
C
10 Double F
UC1 4/6 .18 5.04
UC2 4/6 .65 10.5
11 Double V
cUC1 4/6 .23 6.8
UC2 4/6
12 Double V
UC1 4/6 .16 ND
UC2 4/6 .57 ND
Haplo 13 BM 5/10 4.2 43.2 A
14 BM 7/10 6 55 A
g
PBSC indicates peripheral blood stem cells; CRBI, catheter-related blood stream i
applicable as patient died early after transplantation; UC, umbilical cord; FN, febr
distress syndrome.
* According to National Institutes of Health criteria for severity.In the evaluable patients who initially engrafted, the
percentage of donor chimerism at day 100 and at 1 year is
shown (Figure 2). All evaluable patients achieved 100% donor
myeloid cells by day þ100 and 98% to 100% at 1 year. CD14þ
monocytes and CD3/CD56þ NK cells were between 98% and
100% at both day þ100 and 1 year. The number of CD3þ cells
at day þ100 ranged from 29% to 100%, with a median of 91%.
At 1 year, the range was 65% to 100%, with a median of 93%.nfections after
SCT
GVHD Outcome
Acute Chronic*
RBSI Gr II skin, liver Severe Alive 4.7 yr
FI, CMV
iremia, BSI
Gr IV skin, liver N/A Died d 90: sepsis, GVHD
Gr II skin, gut - Alive 3.2 yr, relapsed
1.4 yr, now 1.8 yr after
second HSCT
- Mild Alive at 2.3 yr
- - Alive 4.5 yr
Gr III skin,
gut, liver
Mild Alive 3.5 yr
- - Alive 2.3 yr
MV, IFI Gr IV skin,
gut, liver
- Rejected 10 mo,
underwent
retransplantation,
died at 1.5 yr
RBSI, IFI,
MV-viremia
- - Developed donor cell
AML 2.5 yr after HSCT
and died at 3 yr
N, endocarditis Gr I-II skin, gut - Alive 3.4 yr
RE sepsis,
andida sepsis
N/A N/A Died d 7: sepsis
RE sepsis Gr I-II gut - Rejected, underwent
retransplantion,
died d 295
RDS N/A N/A Died d 1: ARDS
eromonas sp.
astroenteritis
Gr I skin Alive 8 mo
nfection; IFI, invasive fungal infection; BSI, bloodstream infection; N/A, not
ile neutropenia; BM, bone marrow; ND, not done; ARDS, acute respiratory
Figure 2. Chimerism after HSCT. Percentage of peripheral blood donor
chimerism from myeloid, CD3þ, CD14þ, NK cell fractions, and bone marrow.
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patient with the lowest chimerism (29%) (patient 8) subse-
quently rejected the unrelated donor graft and required
retransplantation. The patient with 39% donor CD3 chime-
rism at day þ100 (patient 1) maintained stable engraftment
and ultimately progressed to 100% donor CD3 chimerism at
2 years after transplantation.
The reconstitution of cell subsets for a single GATA2 pa-
tient before transplantation and at 6 months after trans-
plantation is shown (Figure 3).Clinical Outcome after HSCT
Eight of the 14 (57%) patients in this high-risk cohort of
patients are alive at a median follow-up of 3.5 years (range,
12 months to 5 years) (Figure 4). The overall survival based
on donor type is shown (Figure 4). Mortality was not uni-
formly distributed in the subgroups: 3 of the 4 recipients in
both the MRD and URD groups are alive, and 1 of the 2
haploidentical related donor recipients is alive. However,
only 1 of the 4 UCB recipients survived (Figure 4). Of note, 5
of the 8 survivors (patients 1, 4, 5, 6, 7) had uneventful
hospitalizations and were discharged within 1 month of
transplantation.
In the MRD group, where all 3 survivors have greater than
2 years of follow-up, all patients engrafted with the only
death occurring in the individual on a ventilator at the time
of transplantation (patient 2). However, 1 patient (patient 3)
relapsed 1 year after transplantation and required a second
transplantation using the same sibling donor, preceded by a
myeloablative regimen with busulfan and ﬂudarabine. This
patient remains in complete remission 2 years after
retransplantation. A second patient (patient 1), who was a
lung transplantation candidate before HSCT because of se-
vere pulmonary hypertension and PAP, initially had marked
improvement of his lung disease. However, he subsequently
developed bronchiolitis obliterans and required lung trans-
plantation 4.5 years after HSCT.
In the URD cohort, 3 of the 4 patients are alive with
follow-up greater than 2 years (Figure 4). The only death
occurred in a patient (patient 8) who rejected the URD graft
8 months after transplantation. He underwent retrans-
plantation from a second URD, developed severe GVHD, and
died.
The UCB groupwas themost problematic, with only 1 of 4
patients surviving long-term (Figure 4, Table 3). One patient
(patient 11) died early from sepsis, another patient (patient
10) rejected the double cord graft and died after a salvage
CD34þ-selected haploidentical related donor and single cord
transplantation. The third patient in this group (patient 9)
received a single UCB unit, had delayed engraftment, and did
well for the subsequent 2 years, but ultimately died 2.5 years
after transplantation from a donor cellederived AML. The
only long-term survivor in this cohort (patient 6) developedautoimmune nephrotic syndrome and pancytopenia on day
90, which ultimately responded to treatment with rituximab
and tacrolimus.
In the haploidentical related donor cohort, 1 of the 2 pa-
tients (patient 14) is alive 9months after transplantation. The
ﬁrst patient in this group had progressed to a proliferative
CMML before transplantation, required multiple rounds of
chemotherapy, and had multiple ongoing refractory in-
fections. She died from respiratory failure on day þ1. The
second patient had recurrent gastrointestinal bleeding from
an Epstein-Barr virusepositive T cell lymphoma that
involved her gastrointestinal tract, skin, and lungs and
associated hemophagocytic lymphohistiocytosis. She
received a haploidentical transplantation from her sister and
hadmarked resolution of the lymphoma, including extensive
hydroa vacciniforme-like lesions.
Post-transplantation Complications
We anticipated major infectious complications in this
group of immunocompromised patients. Nine patients (65%)
had infections after transplantation (Table 3) and 3 deaths
were attributable to infection. Overall, the most common
pathogens were bacteria. Three patients had CMV reac-
tivation (but no invasive disease) and 3 had invasive fungal
infections. Surprisingly, none of the patients had reactivation
of their NTM infections after transplantation; however, all
patients with NTM were maintained on antimycobacterial
therapy throughout the conditioning regimen and for at least
3 months after transplantation.
Eight (57%) of the 14 patients had acute GVHD, most
commonly affecting the skin (Table 3). Three patients had
grade III or IV GVHD affecting 2 or more organs. Acute GVHD
was successfully treatedwith steroids (topical or systemic) in
all but patient 2, whose death at 90 days was attributed in
part to severe GVHD, and in patient 8 who developed severe
GVHD after his second transplantation. Acute GVHD was
most common in the MRD group. Chronic GVHD developed
in 3 patients (1, 4, and 6), but was only severe enough to limit
daily activities in 1 patient.
The baseline cytogenetic abnormalities resolved in all
patients except the patient who relapsed and required a
second transplantation (Table 2). This is particularly relevant
in view of the adverse cytogenetics, with monosomy 7 pre-
sent in 5 patients.
Although the groups are too small to derive statistically
signiﬁcant conclusions, there is a trend towards worse
outcome with UCB grafts relative to the URD and MRD
groups, where 75% of patients are still alive.
DISCUSSION
We report the outcome in a cohort of patients with GATA2
deﬁciency who received MRD, URD, UCB, or haploidentical
related donor hematopoietic stem cells after a non-
myeloablative conditioning regimen. In patients with GATA2
deﬁciency, nonmyeloablative allogeneic HSCT results in
reconstitution of the severely deﬁcient monocyte, B, and NK
cell populations, correction of the infection susceptibility
phenotype, and reversal of the propensity for myeloid pro-
gression, including eradication of the abnormal cytogenetic
clones. However, the incidence of graft rejection and relapse
after nonmyeloablative allogeneic HSCT in GATA2 deﬁciency
indicates that alternative transplantation approaches may be
required.
Recently, deﬁcits in the expression of GATA2, a “master
regulator” of hematopoiesis, have been shown to lead to
Figure 3. Reconstitution of CD19þ B cells, NK cells, and monocytes 6 months after transplantation in a GATA2 deﬁcient patient.
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[2e5]. Although HSCT represents the only deﬁnitive therapy
for this disease, the indications for transplantation, optimal
conditioning regimen, timing of transplantation, and donor
source of stem cells remain unclear. In addition, the decision
to undertake allogeneic transplantation has to be weighed
against the complications inherent to HSCT, including
regimen-related toxicity, GVHD, infection, and death.
The development of progressive bone marrow dysplasia
and cytogenetic abnormalities represents 1 of the primary
indications for allogeneic HSCT in GATA2 deﬁciency. GATA2 iscrucial for the maintenance of hematopoietic stem cells in
that both mice and humans with GATA2 deﬁciency lack
multilineage progenitors and have a severe depletion of
granulocyte-macrophage progenitors in the bone marrow
[15e17]. This defect in cell production typically evolves into a
hypocellular MDS and ultimately progresses to AML or a
proliferative CMML.
The largest series published on patients with mutations
in GATA2 found that 84% of patients with GATA2 deﬁciency
met criteria for MDS on bone marrow biopsy [6]. Similarly, a
high frequency of GATA2 mutations was reported in 14
Figure 4. Kaplan-Meier curves showing overall survival according to type of
donor.
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[15]. In this cohort, the risk of malignant transformationwas
high with 6 of the 14 patients developing refractory cyto-
penia with multilineage dysplasia and 4 developing AML.
The median age at diagnosis of MDS or AML was 15 years
(range, 7 to 35). Of note, none of the patients treated with
chemotherapy alone survived (median survival of 1.5 years
after diagnosis of AML).
The majority of patients with GATA2 deﬁciency have low
or intermediate-1 International Prognostic Scoring System
(IPSS) scores at the time of diagnosis [16,17]. All 14 of the
patients in this study had low or intermediate-1 IPSS scores
when diagnosed. According to the IPSS, the time for 25% of
low-risk MDS patients to transform to AML is 9.4 years [16].
However, in our cohort, 2 of 4 patients with low-risk IPSS
scores had a rapid transformation from a hypocellular MDS
to a hypercellular MDS/refractory anemia with excess blasts.
Thus, once the diagnosis of GATA2 deﬁciency is established,
close follow-up of these patients is warranted, and patients
should be considered for transplantation even before the
appearance of blasts in their bone marrow.
The development of recurrent severe infections is a sec-
ond indication to proceed to allogeneic HSCT. A subset of
patients with mutations in GATA2 present in their second or
third decade of life with recurrent life-threatening oppor-
tunistic infections (frequently NTM), but they lack features of
a malignant hematologic disease [6]. The mortality associ-
ated with these infections is enough to warrant replacement
of the dysfunctional and deﬁcient immune system. This is
exempliﬁed in 2 20-year-old patients in our study who died
awaiting transplantation within the preceding year: 1 pa-
tient died from sepsis and 1 died from CMV pneumonia (D.
Hickstein, unpublished data).
Progressive lung injury from infection and PAP represents
a third reason for allogeneic HSCT in patients with GATA2
deﬁciency. Both frequent pneumonias as well as PAP result in
gradual deterioration of lung function. The ﬁrst 2 patients
who underwent transplantation on this protocol had severe
PAP requiring pulmonary lavage before transplantation, and
both required supplemental oxygen at the time of trans-
plantation. As mentioned previously, 1 patient has gone on to
require bilateral lung transplantation and the other died
early after transplantation. Therefore, initiating allogeneic
HSCT before PAP develops would be anticipated to result in
lower post-transplantation morbidity.
The ideal pretransplantation conditioning regimen for
GATA2 deﬁciency is unclear. Moreover, it is likely that thestage of the disease at the time of transplantation may in-
ﬂuence the type of conditioning. This study was initiated
before the identiﬁcation of the GATA2 gene as the cause of
MonoMAC syndrome, and all of the initial patients had
considerable comorbidities necessitating a nonmyeloablative
approach to allogeneic HSCT in this cohort. However, relapse
in 1 of the 4 MRD recipients and graft rejection in 1 of the 4
recipients from each of the URD and UBC groups support the
use of amore intensive conditioning regimen. Also, 3 patients
required pretransplantation chemotherapy, which may have
been unnecessary if a myeloablative regimen were used.
The timing of HSCT is well deﬁned for many malig-
nancies; however, the timing of allotransplantation is less
clear for many immune deﬁciencies. GATA2 deﬁciency is
particularly difﬁcult, given its variable natural history with
some patients developing symptoms only after many de-
cades. However, after symptoms develop, survival declines
[6]. The uninterrupted progression of GATA2 deﬁciency that
we have seen suggests that the ideal time for transplantation
would be after the onset of pathologic abnormalities, but
before the development of organ damage or malignancy.
Identifying more precise indicators of disease progression is
urgently needed.
In this regard, we are currently investigating markers that
portend myeloid progression. For example, it is well known
that acquired mutations lead to poor-risk MDS/AML. To
identify acquired somatic mutations associated with myeloid
transformation in patients with GATA2 deﬁciency, we
sequenced the region of the ASXL1 gene previously shown to
be associated with transformation from MDS to AML [8,17].
Heterogeneous somatic ASXL1 mutations were identiﬁed in
nearly 30% of patients, including 4 out of 5 patients who
developed a proliferative CMML. Patients with GATA2 and
ASXL1 mutations were considerably younger and almost
exclusively female compared with patients with MDS and
ASXL1 alone [8,17].
Donor source remains a critical variable in the outcome of
HSCT and this is evident in our study. MRD and URD trans-
plantations were associated with the best outcomes, with
75% survival in both groups. The poor outcome with UCB
supports the use of alternative donor sources, such as hap-
loidentical related donors in cases where a 10/10-matched
donor is not available. The rapid reconstitution of the deﬁ-
cient compartments is essential to clear the ongoing in-
fections that affect many of the patients at the time of
transplantation. As such, the prolonged time to engraftment
with UCB transplantation is especially detrimental in this
population.
Previously, patients with GATA2 deﬁciency underwent
transplantation without prior knowledge of the genetic
defect. Bigley et al. described 2 patients ages 12 and 21 who
received URD transplants for GATA2 deﬁciency and both
were alive 2 years after transplantation [17]. In a report of
patients with Emberger’s syndrome, 4 young patients (ages
9,11,12, and 16) received HSCT, primarily fromURD, and only
1 survived [18]. In contrast, all 6 of the 14 patients in the
French registry study who developed MDS or AML and un-
derwent allotransplantationwere alive at a median of 2 years
after transplantation [15]. Our pilot study in 2011 described
encouraging results using a nonmyeloablative regimen in 6
patients with GATA2 deﬁciency [9]. However, with further
follow-up of the original cohort, and the inclusion of 8
additional patients, it now appears that more intensive
conditioning is indicated in patients with GATA2 deﬁciency.
Lastly, our overall mortality (42%) in this high-risk group of
J. Grossman et al. / Biol Blood Marrow Transplant 20 (2014) 1940e19481948patients, though heavily skewed by the poor outcome of UCB
recipients, is comparable to recently reported trans-
plantation outcomes [19].
In summary, although nonmyeloablative HSCT results in
reversal of the hematologic, immunologic, and clinical
manifestations of GATA2 deﬁciency, more uniform engraft-
ment and a reduced risk of relapsewould be anticipatedwith
a more intensive conditioning regimen. To this end, we are
now using a myeloablative regimen with busulfan and ﬂu-
darabine for patients with GATA2 deﬁciency [20,21]. The
optimal time to transplantation appears to be during the
hypocellular MDS phase and before signiﬁcant organ
dysfunction develops. We anticipate that with the increasing
frequency of genetic testing for GATA2 mutations, patients
will undergo transplantation earlier in the course of the
disease, before signiﬁcant organ damage or clonal evolution
of MDS to AML or CMML occurs, and that the outcome of
allogeneic HSCT in these patients will continue to improve.
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